Decreased brain levels of coenzyme Q
10 (CoQ
10), an endogenously synthesized lipophilic antioxidant
1,2, underpin encephalopathy in primary CoQ
10 deficiencies
3,4 and are associated with common neurodegenerative diseases and the ageing process
5,6. CoQ
10 supplementation does not increase CoQ
10 pools in the brain or in other tissues. The recent discovery of the mammalian CoQ
10 headgroup synthesis pathway, in which 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) makes 4-hydroxymandelate (4-HMA) to synthesize the CoQ
10 headgroup precursor 4-hydroxybenzoate (4-HB)
7, offers an opportunity to pharmacologically restore CoQ
10 synthesis and mechanistically treat CoQ
10 deficiencies. To test whether 4-HMA or 4-HB supplementation promotes CoQ
10 headgroup synthesis in vivo, here we administered 4-HMA and 4-HB to
Hpdl−/− mice, which model an ultra-rare, lethal mitochondrial encephalopathy in humans. Both 4-HMA and 4-HB were incorporated into CoQ
9 and CoQ
10 in the brains of
Hpdl−/− mice. Oral treatment of
Hpdl−/− pups with 4-HMA or 4-HB enabled 90–100% of
Hpdl−/− mice to live to adulthood. Furthermore, 4-HB treatment stabilized and improved the neurological symptoms of a patient with progressive spasticity due to biallelic
HPDL variants. Our work shows that 4-HMA and 4-HB can modify the course of mitochondrial encephalopathy driven by
HPDL variants and demonstrates that CoQ
10 headgroup intermediates can restore CoQ
10 synthesis in vivo.